A generic version of a widely used type 2 diabetes medication is now available in the United States for the first time. The drug combines two established treatments for blood sugar management into a single extended-release tablet.
Par Health announced the launch of the first and only generic version of Janumet XR, which contains sitagliptin and metformin hydrochloride in an extended-release formulation, according to a press release distributed by PR Newswire. The brand-name version, Janumet XR, has been prescribed for years to adults managing type 2 diabetes.
Sitagliptin belongs to a class of drugs known as DPP-4 inhibitors, which work by helping the body produce more insulin when blood sugar levels are high and reducing the amount of glucose the liver produces. Metformin is one of the most commonly prescribed diabetes medications in the world and works by decreasing glucose production in the liver while improving the body's sensitivity to insulin.
The extended-release formulation is designed to be taken less frequently than immediate-release versions and may reduce some of the gastrointestinal side effects associated with metformin, which can include nausea, stomach upset, and diarrhea, particularly when treatment begins.
Generic drugs are required by the Food and Drug Administration to contain the same active ingredients in the same dosage and form as their brand-name equivalents and must meet the same standards for quality, strength, and purity. The availability of a generic version typically reduces the cost of a medication significantly, which can affect how many patients are able to access and stay on their prescribed treatment.
Type 2 diabetes affects tens of millions of Americans. Managing blood sugar over the long term typically requires medication alongside lifestyle changes, and cost has been a persistent barrier for some patients in maintaining consistent treatment. The arrival of a generic option for a combination drug like Janumet XR may provide an alternative for patients and prescribers looking to reduce out-of-pocket costs.
Par Health's launch makes it the first company to offer this specific generic product in the American market. The timing of a generic launch is often tied to the expiration of patents held by the brand-name manufacturer.
